Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease. - Archive ouverte HAL Access content directly
Journal Articles BMC Medicine Year : 2012

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.

(1) , (1) , (2) , (3) , (4) , (5) , (5) , (6) , (7) , (6) , (1) , (1)
1
2
3
4
5
6
7
Gemma Bruera
  • Function : Author
  • PersonId : 934055
Katia Cannita
  • Function : Author
  • PersonId : 934056
Daniela Di Giacomo
  • Function : Author
  • PersonId : 934057
Aude Lamy
  • Function : Author
  • PersonId : 934058
Antonella Dal Mas
  • Function : Author
  • PersonId : 934060
Gino Coletti
  • Function : Author
  • PersonId : 934061
Corrado Ficorella
  • Function : Author
  • PersonId : 934062
Enrico Ricevuto
  • Function : Correspondent author
  • PersonId : 934063

Connectez-vous pour contacter l'auteur

Abstract

ABSTRACT: BACKGROUND: Bevacizumab (BEV) plus triplet chemotherapy can increase efficacy of first-line treatment of metastatic colorectal cancer (MCRC), particularly integrated with secondary liver surgery in liver-limited (L-L) patients. The prognostic value of the KRAS genotype in L-L and other or multiple metastatic (O/MM) MCRC patients treated with the FIr-B/FOx regimen was retrospectively evaluated. METHODS: Tumoral and metastatic samples were screened for KRAS codon 12 and 13 and BRAF mutations by SNaPshot and/or direct sequencing. Fit MCRC patients <75 years were consecutively treated with FIr-B/FOx regimen: weekly 12-h timed flat-infusion/5-fluorouracil (TFI 5-FU) 900 mg/m2, days 1, 2, 8, 9, 15, 16, 22 and 23; irinotecan (CPT-11) 160 mg/m2 plus BEV 5 mg/kg, days 1, 15; oxaliplatin (OXP) 80 mg/m2, days 8, 22; every 4 weeks. MCRC patients were classified as L-L and O/MM. Activity and efficacy were evaluated and compared using log-rank test. RESULTS: In all, 59 patients were evaluated: 31 KRAS wild-type (53%), 28 KRAS mutant (47%). At 21.5 months median follow-up, objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were, respectively: KRAS wild-type 90%, 14 months, 38 months; KRAS mutant 67%, 11 months, 20 months. PFS and OS were not significantly different. PFS and OS were significantly different in L-L compared to O/MM evaluable patients. In KRAS wild-type patients, clinical outcome of 12 L-L compared to 18 O/MM was significantly different: PFS 21 versus 12 months and OS 47 versus 28 months, respectively. In KRAS mutant patients, the clinical outcome of 13 L-L compared to 14 O/MM was not significantly different: PFS 11 months equivalently and OS 39 versus 19 months, respectively. CONCLUSIONS: The KRAS genotype wild-type and mutant does not significantly affect different clinical outcomes for MCRC patients treated with the first-line FIr-B/FOx intensive regimen. KRAS wild-type patients with L-L disease may achieve a significantly prolonged clinical outcome due to integration with secondary liver surgery, with respect to KRAS mutant patients.
Fichier principal
Vignette du fichier
1741-7015-10-135.pdf (222.13 Ko) Télécharger le fichier
Vignette du fichier
1741-7015-10-135.xml (99.25 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other
Loading...

Dates and versions

inserm-00764322 , version 1 (12-12-2012)

Identifiers

Cite

Gemma Bruera, Katia Cannita, Daniela Di Giacomo, Aude Lamy, Giancarlo Troncone, et al.. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.. BMC Medicine, 2012, 10 (1), pp.135. ⟨10.1186/1741-7015-10-135⟩. ⟨inserm-00764322⟩
85 View
204 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More